DBV Technologies (DBVT) PT Set at $57.00 by Citigroup
DBV Technologies (NASDAQ:DBVT) received a $57.00 price target from analysts at Citigroup in a report issued on Wednesday. The firm currently has a “buy” rating on the stock. Citigroup’s target price would suggest a potential upside of 117.31% from the stock’s current price.
A number of other brokerages have also commented on DBVT. BidaskClub upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Leerink Swann set a $49.00 price target on shares of DBV Technologies and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Morgan Stanley lowered shares of DBV Technologies from an “overweight” rating to an “equal weight” rating in a research note on Monday, October 23rd. Zacks Investment Research lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Monday, December 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of DBV Technologies in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. DBV Technologies currently has a consensus rating of “Hold” and a consensus price target of $49.63.
Shares of DBV Technologies (DBVT) opened at $26.23 on Wednesday. DBV Technologies has a 12 month low of $20.08 and a 12 month high of $50.57.
WARNING: “DBV Technologies (DBVT) PT Set at $57.00 by Citigroup” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/15/dbv-technologies-dbvt-pt-set-at-57-00-by-citigroup.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.